A Phase 1, Randomized, Partially Blinded, Placebo and Positive Controlled, 3-Period, Six-Sequence, Single and Multiple-Dose Cross-Over Study to Assess the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Partially Blinded, Placebo and Positive Controlled, 3-Period, Six-Sequence, Single and Multiple-Dose Cross-Over Study to Assess the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Ledipasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top